Evaluation of the Interactions of Cabozantinib with Topoisomerase Enzymes by in vitro Enzyme Activity Assays, and its Effects on Cancer Cell Proliferation
Abstract
The discovery of many drugs in recent years provides a definitive solution in the treatment of various diseases, but today, despite the discovery of many effective anticancer drugs, there are various types of cancer that have limitations in treatment and are still not completely curable. Since most of these limitations are due to cancer cells gaining resistance or compounds only being effective in certain types of cancer cells, the search for more effective anticancer drugs that are also effective in these types of cancer is inevitable. Cabozantinib is in medical use as a highly effective anticancer drug in various types of cancer, such as medullary thyroid cancer and kidney cancer. The anticancer properties of the Cabozantinib compound have attracted more attention in recent years, however, more studies are needed to define the anticancer activities of this compound. In our study, the interactions of Cabozantinib with topoisomerase enzymes, were demonstrated through in vitro enzyme activity tests, and the anti-proliferative effect of Cabozantinib was studied on MCF7, A549 and PC3 cell lines. By analyzing the interactions of the Cabozantinib with topoisomerases, the action mechanisms of the compound at the molecular level was evaluated.
Keywords
Topoisomerase enzymes, Cancer, CabozanJnib, Tyrosine kinase inhibitor, DNA damage.
Supporting Institution
TÜBİTAK-2209A ve CÜBAP
Project Number
TÜBİTAK-2209A-(1919B011701745) ve CÜBAP (ECZ018)
References
- [1] Wang J.C., Cellular roles of DNA topoisomerases: a molecular perspective, Nat Rev Mol Cell Biol., 3 (2002) 430-440.
- [2] Carey J.F., Schultz S.J., Sisson L., Fazzio T.G., Champoux J.J., DNA relaxation by human topoisomerase I occurs in the closed clamp conformation of the protein, Proc Natl Acad Sci USA, 100 (10) (2003) 5640-5645.
- [3] Skok Ž., Zidar N., Kikelj D., Ilaš J., Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets, J Med Chem., 63 (2020) 884-904.
- [4] Nitiss J.L., Investigating the biological functions of DNA topoisomerases in eukaryotic cells, Biochim Biophys Acta, 1400 (1-3) (1998) 63-81.
- [5] Bjornsti M.A., Osheroff N., Introduction to DNA Topoisomerases, Methods Mol Biol., 94 (1999) 1-8.
- [6] Pommier Y., Leo E., Zhang H., Marchand C., DNA topoisomerases and their poisoning by anticancer and antibacterial drugs, Chem Biol. 17 (2010) 421-433.
- [7] Swedan H.K., Kassab A.E., Gedawy E.M., Elmeligie S.E., Topoisomerase II inhibitors design: Early studies and new perspectives, Bioorg Chem. 136 (2023) 106548.
- [8] Champoux J.J., DNA Topoisomerases: Structure, Function, and Mechanism, Annu Rev Biochem, 70 (2001) 369-413.
- [9] Cinelli M.A., Topoisomerase 1B poisons: Over a half-century of drug leads, clinical candidates, and serendipitous discoveries, Med Res Rev. 39 (2019) 1294-1337.
- [10] Baglini E., Salerno S., Barresi E., Robello M., Da Settimo F., Taliani S., Marini A.M., Multiple Topoisomerase I (TopoI), Topoisomerase II (TopoII) and Tyrosyl-DNA Phosphodiesterase (TDP) inhibitors in the development of anticancer drugs, Eur J Pharm Sci., 156 (2021) 105594.